IS5378A - Apríl-nýstárlegt prótín sem hefur áhrif á vöxt - Google Patents

Apríl-nýstárlegt prótín sem hefur áhrif á vöxt

Info

Publication number
IS5378A
IS5378A IS5378A IS5378A IS5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A
Authority
IS
Iceland
Prior art keywords
april
affects growth
innovative protein
innovative
protein
Prior art date
Application number
IS5378A
Other languages
English (en)
Icelandic (is)
Inventor
Tschopp Jurg
Original Assignee
Apotech Research And Development Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Research And Development Ltd. filed Critical Apotech Research And Development Ltd.
Publication of IS5378A publication Critical patent/IS5378A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS5378A 1997-09-12 2000-02-18 Apríl-nýstárlegt prótín sem hefur áhrif á vöxt IS5378A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
IS5378A true IS5378A (is) 2000-02-18

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5378A IS5378A (is) 1997-09-12 2000-02-18 Apríl-nýstárlegt prótín sem hefur áhrif á vöxt

Country Status (20)

Country Link
US (3) US20030138884A1 (https=)
EP (1) EP1027431A2 (https=)
JP (1) JP2001515712A (https=)
KR (1) KR100618492B1 (https=)
CN (1) CN1195849C (https=)
AU (1) AU759717B2 (https=)
BR (1) BR9812634A (https=)
CA (1) CA2303615A1 (https=)
CZ (1) CZ294615B6 (https=)
EA (1) EA005411B1 (https=)
EE (1) EE200000147A (https=)
HU (1) HUP0004611A3 (https=)
IL (1) IL134537A0 (https=)
IS (1) IS5378A (https=)
NO (1) NO20001242L (https=)
NZ (1) NZ503850A (https=)
PL (1) PL339463A1 (https=)
SK (1) SK3542000A3 (https=)
TR (1) TR200000669T2 (https=)
WO (1) WO1999012965A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
AU5201399A (en) * 1997-09-30 1999-10-18 Pharmacia & Upjohn Company Tnf-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Ma Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (en) * 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1934258B1 (en) * 2005-09-26 2011-03-02 Enzo Life Sciences (ELS) AG Antibodies against april as biomarkers for early prognosis of lymphoma patients
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CA2754127C (en) 2009-03-02 2017-04-18 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
TR201901782T4 (tr) * 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
RU2671101C1 (ru) * 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
FI3380522T3 (fi) 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
EP4237121A1 (en) 2020-10-29 2023-09-06 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
KR20240053675A (ko) 2021-08-11 2024-04-24 악소 바이오파마슈티컬 인코포레이티드 sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
AU726486C (en) * 1996-03-14 2004-02-05 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
KR20010023893A (ko) 2001-03-26
EA200000310A1 (ru) 2000-10-30
JP2001515712A (ja) 2001-09-25
NZ503850A (en) 2002-12-20
NO20001242L (no) 2000-05-11
SK3542000A3 (en) 2000-08-14
CN1270632A (zh) 2000-10-18
PL339463A1 (en) 2000-12-18
CN1195849C (zh) 2005-04-06
NO20001242D0 (no) 2000-03-09
CA2303615A1 (en) 1999-03-18
KR100618492B1 (ko) 2006-08-31
WO1999012965A2 (en) 1999-03-18
CZ294615B6 (cs) 2005-02-16
EA005411B1 (ru) 2005-02-24
HUP0004611A3 (en) 2002-04-29
HUP0004611A2 (hu) 2001-04-28
BR9812634A (pt) 2000-08-22
EE200000147A (et) 2001-02-15
AU759717B2 (en) 2003-04-17
WO1999012965A3 (en) 1999-06-03
AU9316298A (en) 1999-03-29
TR200000669T2 (tr) 2000-08-21
CZ2000869A3 (cs) 2000-09-13
EP1027431A2 (en) 2000-08-16
US20030138884A1 (en) 2003-07-24
IL134537A0 (en) 2001-04-30
US20060084148A1 (en) 2006-04-20
US20050112596A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
IS5378A (is) Apríl-nýstárlegt prótín sem hefur áhrif á vöxt
DE69729021D1 (de) Flächiges Implantat
DE69800491D1 (de) Baumschere
NO2010022I1 (no) Denosumab
NO982097D0 (no) Peptider
DE69725567D1 (de) Haltetransplantat
NO982098L (no) Peptider
ITMI992109A0 (it) Innesto
ATE295417T1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
GB9828704D0 (en) Proteins
GB9816337D0 (en) Proteins
GB9828880D0 (en) Protein
DE59810662D1 (de) Koaxialverbinder
ID20403A (id) PEMBUATAN α-TOKOFEROL
ATE266679T1 (de) Wachse
GB9819038D0 (en) Protein
GB9809566D0 (en) Protein
GB9812607D0 (en) Protein
KR970020372U (ko) 장제용 화환
GB9816336D0 (en) Proteins
GB9816335D0 (en) Proteins
GB0320970D0 (en) Proteins
DK1088069T3 (da) Angiostatin-bindende protein
GB9823975D0 (en) Protein